192 related articles for article (PubMed ID: 34445492)
1. Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition.
Ren N; Liu Q; Yan L; Huang Q
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445492
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer.
Jin HJ; Jung S; DebRoy AR; Davuluri RV
Oncotarget; 2016 Aug; 7(34):54616-54626. PubMed ID: 27409348
[TBL] [Abstract][Full Text] [Related]
3. The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.
Ramanand SG; Chen Y; Yuan J; Daescu K; Lambros MB; Houlahan KE; Carreira S; Yuan W; Baek G; Sharp A; Paschalis A; Kanchwala M; Gao Y; Aslam A; Safdar N; Zhan X; Raj GV; Xing C; Boutros PC; de Bono J; Zhang MQ; Mani RS
J Clin Invest; 2020 Aug; 130(8):3987-4005. PubMed ID: 32343676
[TBL] [Abstract][Full Text] [Related]
4. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus.
Zhang X; Cowper-Sal lari R; Bailey SD; Moore JH; Lupien M
Genome Res; 2012 Aug; 22(8):1437-46. PubMed ID: 22665440
[TBL] [Abstract][Full Text] [Related]
5. Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
Bu H; Narisu N; Schlick B; Rainer J; Manke T; Schäfer G; Pasqualini L; Chines P; Schweiger MR; Fuchsberger C; Klocker H
Hum Mutat; 2016 Jan; 37(1):52-64. PubMed ID: 26411452
[TBL] [Abstract][Full Text] [Related]
6. A rare variant, which destroys a FoxA1 site at 8q24, is associated with prostate cancer risk.
Hazelett DJ; Coetzee SG; Coetzee GA
Cell Cycle; 2013 Jan; 12(2):379-80. PubMed ID: 23255135
[No Abstract] [Full Text] [Related]
7. Identification of a regulatory variant that binds FOXA1 and FOXA2 at the CDC123/CAMK1D type 2 diabetes GWAS locus.
Fogarty MP; Cannon ME; Vadlamudi S; Gaulton KJ; Mohlke KL
PLoS Genet; 2014 Sep; 10(9):e1004633. PubMed ID: 25211022
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
9. Integrative functional genomics identifies regulatory genetic variant modulating RAB31 expression and altering susceptibility to breast cancer.
Zhang Y; Yang B; Cheng X; Liu L; Zhu Y; Gong Y; Yang Y; Tian J; Peng X; Zou D; Yang L; Mei S; Wang X; Lou J; Ke J; Li J; Gong J; Chang J; Yuan P; Zhong R
Mol Carcinog; 2018 Dec; 57(12):1845-1854. PubMed ID: 30182384
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in RNA-induced silencing complex genes and prostate cancer.
Nikolić Z; Savić Pavićević D; Vučić N; Cerović S; Vukotić V; Brajušković G
World J Urol; 2017 Apr; 35(4):613-624. PubMed ID: 27498138
[TBL] [Abstract][Full Text] [Related]
12. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.
Mazrooei P; Kron KJ; Zhu Y; Zhou S; Grillo G; Mehdi T; Ahmed M; Severson TM; Guilhamon P; Armstrong NS; Huang V; Yamaguchi TN; Fraser M; van der Kwast T; Boutros PC; He HH; Bergman AM; Bristow RG; Zwart W; Lupien M
Cancer Cell; 2019 Dec; 36(6):674-689.e6. PubMed ID: 31735626
[TBL] [Abstract][Full Text] [Related]
13. Gene regulatory mechanisms underpinning prostate cancer susceptibility.
Whitington T; Gao P; Song W; Ross-Adams H; Lamb AD; Yang Y; Svezia I; Klevebring D; Mills IG; Karlsson R; Halim S; Dunning MJ; Egevad L; Warren AY; Neal DE; Grönberg H; Lindberg J; Wei GH; Wiklund F
Nat Genet; 2016 Apr; 48(4):387-97. PubMed ID: 26950096
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
15. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells.
Zhang Z; Chng KR; Lingadahalli S; Chen Z; Liu MH; Do HH; Cai S; Rinaldi N; Poh HM; Li G; Sung YY; Heng CL; Core LJ; Tan SK; Ruan X; Lis JT; Kellis M; Ruan Y; Sung WK; Cheung E
Genome Res; 2019 Feb; 29(2):223-235. PubMed ID: 30606742
[TBL] [Abstract][Full Text] [Related]
16. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
17. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.
Huang Q; Whitington T; Gao P; Lindberg JF; Yang Y; Sun J; Väisänen MR; Szulkin R; Annala M; Yan J; Egevad LA; Zhang K; Lin R; Jolma A; Nykter M; Manninen A; Wiklund F; Vaarala MH; Visakorpi T; Xu J; Taipale J; Wei GH
Nat Genet; 2014 Feb; 46(2):126-35. PubMed ID: 24390282
[TBL] [Abstract][Full Text] [Related]
18. Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci.
Zhang P; Tillmans LS; Thibodeau SN; Wang L
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31323811
[TBL] [Abstract][Full Text] [Related]
19. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
20. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
